Targeting PSG1 to enhance chemotherapeutic efficacy: new application for anti-coagulants Dicumarol

In this study, we analyzed the gene expression profiles of preoperative samples from ER-negative breast cancer patients with different responses to taxane-anthracycline-based (TA-based) chemotherapy, and identified a group of genes that was predictive. Pregnancy specific beta-1-glycoprotein 1 (PSG1) played a central role within signaling pathways of these genes. Inhibiting the PSG1 can effectively reduce chemoresistance via transforming growth factor-β (TGF-β)-related pathway in ER-negative breast cancer cells. Drug screening then identified dicumarol (DCM) to target the PSG1 and inhibited chemoresistance to TA-based chemotherapy in vitro , in vivo , and in clinicalsamples. Taken together, this study highlight PSG1 as an important mediator of chemoresistance, whose effect could be diminished by DCM.

Source: Clinical Science - September 20, 2016 Category: Biomedical Science Authors: He, D.-x., Gu, F., Wu, J., Gu, X.-T., Lu, C.-x., Mao, A.-q., Zhang, G.-y., Ding, Z.-y., Wang, J.-k., Hao, J.-j., Fu, L., Ma, X. Tags: PublishAheadOfPrint Source Type: research